SELLAS Life Sciences (SLS) Other Non-Current Assets (2010 - 2026)
SELLAS Life Sciences (SLS) reported Other Non-Current Assets of $255000.0 for Q1 2026, down 3.04% year-over-year from $263000.0 in Q1 2025, and down 0.78% on a QoQ basis from $257000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Other Non-Current Assets data on file, last reported at $255000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 3.04% year-over-year to $255000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $255000.0 (down 3.04% YoY) and the FY2025 annual result came in at $257000.0, down 3.38% from the prior year.
- Other Non-Current Assets retreated to $255000.0 in Q1 2026 per SLS's latest filing, from $257000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $554000.0 in Q1 2022 and bottomed at $34000.0 in Q3 2025.
- The 5-year median for Other Non-Current Assets is $272000.0 (2024), against an average of $313294.1.
- The widest annual swing landed in 2024, when Other Non-Current Assets plunged 88.59%; it then decreased 3.04% in 2026.
- Tracing SLS's Other Non-Current Assets over 5 years: stood at $399000.0 in 2022, then sank by 31.08% to $275000.0 in 2023, then declined by 3.27% to $266000.0 in 2024, then retreated by 3.38% to $257000.0 in 2025, then slipped by 0.78% to $255000.0 in 2026.
- Per Business Quant, the three latest SLS Other Non-Current Assets figures stand at $255000.0 (Q1 2026), $257000.0 (Q4 2025), and $34000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 255,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 255,000.00 |
| Dec 31, 2025 | 257,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 263,000.00 |
| Dec 31, 2024 | 266,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 275,000.00 |
| Sep 30, 2023 | 377,000.00 |
| Jun 30, 2023 | 381,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 399,000.00 |
| Sep 30, 2022 | 521,000.00 |
| Jun 30, 2022 | 514,000.00 |
| Mar 31, 2022 | 554,000.00 |
| Dec 31, 2021 | 594,000.00 |
| Sep 30, 2021 | 597,000.00 |
| Jun 30, 2021 | 623,000.00 |
| Mar 31, 2021 | 676,000.00 |
| Dec 31, 2020 | 614,000.00 |
| Sep 30, 2020 | 651,000.00 |
| Jun 30, 2020 | 687,000.00 |
| Mar 31, 2020 | 499,000.00 |
| Dec 31, 2019 | 536,000.00 |
| Sep 30, 2019 | 115,000.00 |
| Jun 30, 2019 | 114,000.00 |
| Mar 31, 2019 | 114,000.00 |
| Dec 31, 2018 | 663,000.00 |
| Sep 30, 2018 | 1.15 Mn |
| Jun 30, 2018 | 1.53 Mn |
| Mar 31, 2018 | 899,000.00 |
| Dec 31, 2017 | 925,000.00 |
| Sep 30, 2017 | 830,000.00 |
| Jun 30, 2017 | 189,000.00 |
| Mar 31, 2017 | 367,000.00 |
| Dec 31, 2016 | 41,000.00 |
| Jun 30, 2016 | 218,000.00 |
| Mar 31, 2016 | 88,000.00 |
| Dec 31, 2015 | 392,000.00 |
| Sep 30, 2015 | 176,000.00 |
| Jun 30, 2015 | 78,000.00 |
| Mar 31, 2015 | 82,000.00 |
| Dec 31, 2014 | 87,000.00 |
| Sep 30, 2014 | 88,000.00 |
| Jun 30, 2014 | 108,000.00 |
| Mar 31, 2014 | 104,000.00 |
| Dec 31, 2013 | 115,000.00 |
| Sep 30, 2013 | 129,000.00 |
| Jun 30, 2013 | 142,000.00 |
| Mar 31, 2013 | 74,000.00 |
| Dec 31, 2012 | 74,000.00 |
| Sep 30, 2012 | 74,000.00 |
| Mar 31, 2012 | 3,000.00 |
| Dec 31, 2011 | 3,000.00 |
| Sep 30, 2011 | 3,000.00 |
| Jun 30, 2011 | 16,000.00 |
| Dec 31, 2010 | 16,000.00 |